Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab Plus FOLFOXIRI vs FOLFOX in Unresectable Colorectal Liver Metastasis
NCT03493048Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2018
- Primary completion
- Dec 2022
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in colorectal cancer (CRC), sponsored by Sun Yat-sen University. Started Apr 2018; status: active, not recruiting.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03493048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03493048.